Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + Intensive Chemotherapy in Newly Diagnosed AML
NCT06226571Phase 1Active, not recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- May 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML), sponsored by Syndax Pharmaceuticals. Primary endpoints: Dose-limiting Toxicities at Day 42 and Treatment-emergent Adverse Events. Started May 2024; status: active, not recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06226571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226571.